← Back

Sinopharm Group Co Ltd

Sinopharm Group Co. Ltd. is a Chinese company engaged in the wholesale and retail of pharmaceutical and healthcare products and medical devices. It operates through four segments: Pharmaceutical Distribution, Medical Devices Distribution, Retail Pharmacy, and Other Business. The company also provides logistics, value-added services, property management, and consulting, and manufactures medicines. Founded in 2003, it is headquartered in Shanghai and is a subsidiary of Sinopharm Industrial Investment Co., Ltd.

Price · split & dividend adjusted
News & notes moving 1099.HK
China
1099.HK2

Sinopharm Modern to Acquire 51% Stake in Guorui Pharmaceutical for 406 Million Yuan

Sinopharm Modern announced it will acquire a 51% stake in Sinopharm Group Guorui Pharmaceutical for 406 million yuan in cash. The counterparties are Sinopharm Group, Sinopharm Holdings, and Sinopharm Group Medicine. Upon completion, Guorui Pharmaceutical will become a controlled subsidiary of Sinopharm Modern, aiming to eliminate horizontal competition and enrich its product pipeline in areas such as the nervous system and anti-infection. This transaction constitutes a related-party transaction but does not constitute a major asset restructuring, and does not require submission to the shareholders' meeting for review.
Sinopharm Grou…
国药集团国瑞药业 · Capital · Positive Sinopharm Modern acquires 51% of Guorui, making it a controlled subsidiary, which is a positive M&A event for the acquirer.
1099.HK · Capital · Neutral Sinopharm Group is a counterparty selling its stake in Guorui, but the impact on Sinopharm Group itself is not detailed.
Read original ↗
央广财经·48dRead more →
China
1099.HK▼

Sinopharm Accord's first-half 2026 net profit falls 8.97% year on year

Sinopharm Group announced that Sinopharm Accord has released its first-half 2026 performance flash report. Net profit attributable to shareholders of the listed company was 606 million yuan, down 8.97% year on year. During the reporting period, Sinopharm Accord achieved total operating revenue of 36.266 billion yuan, down 1.44% year on year. Operating profit was 834 million yuan, down 9.94%. Total profit was 827 million yuan, down 9.88%. Net profit attributable to shareholders of the listed company after deducting non-recurring gains and losses was 599 million yuan, down 6.84%. Basic earnings per share were 0.99 yuan, down 9.17%. The weighted average return on equity was 3.21%, down 0.49 percentage points year on year. At the end of the reporting period, the company's total assets were 48.171 billion yuan, down 1.89% year on year. Equity attributable to shareholders of the listed company was 18.873 billion yuan, up 1.42% year on year. Total share capital was 612 million shares, up 10.00% year on year. Net assets per share attributable to shareholders of the listed company were 30.83 yuan, up 1.41% year on year.
China National… ▼Sinopharm Grou… ▼
000028.CS · Capital · Negative Sinopharm Accord's first-half 2026 net profit fell 8.97% year on year, with revenue and operating profit also declining.
1099.HK · Capital · Negative Sinopharm Group's subsidiary Sinopharm Accord reported lower first-half 2026 net profit, reflecting negatively on the parent.
Read original ↗
南方财经网·50dRead more →
© 2026 MarketIVAsset